Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN.

J Clin Oncol. 2015 Jan 1;33(1):58-64. doi: 10.1200/JCO.2014.56.3296. Epub 2014 Nov 24.

2.

A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102.

Gralow JR, Barlow WE, Lew D, Dammann K, Somlo G, Rinn KJ, Vogel SJ, Wong L, Livingston RB, Hortobagyi GN.

Breast Cancer Res Treat. 2014 Jan;143(2):351-8. doi: 10.1007/s10549-013-2797-2. Epub 2013 Dec 19.

3.

A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.

Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW.

Clin Cancer Res. 2009 Sep 15;15(18):5937-44. doi: 10.1158/1078-0432.CCR-08-3282. Epub 2009 Sep 1.

4.

[Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Charlop AW, Tseng J, Rinn KJ, Livingston RB.

Nucl Med Biol. 2002 Oct;29(7):719-27.

PMID:
12381452
5.

Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.

Stafford SE, Gralow JR, Schubert EK, Rinn KJ, Dunnwald LK, Livingston RB, Mankoff DA.

Acad Radiol. 2002 Aug;9(8):913-21.

PMID:
12186440

Supplemental Content

Support Center